Table 2 Superior efficacy of inhaled dry powder 5AZA on tumour burden in an orthotopic rat lung cancer model.

From: 5-Azacytidine inhaled dry powder formulation profoundly improves pharmacokinetics and efficacy for lung cancer therapy through genome reprogramming

Treatment groups

Cell line

Tumour type

Air

Aqueous

Dry powder

Tumour Burden (gms)

Calu6

AdC

12.6 ± 4.3

6.2 ± 2.61

2.4 ± 1.2a,b

Calu3

AdC

6.5 ± 2.1

3.1 ± 0.91

1.9 ± 0.9a,b

H358

In Situ C

7.8 ± 3.6

0.4 ± 0.21

0.3 ± 0.4a

RH2

SCC

14.1 ± 3.0

9.6 ± 2.11

4.0 ± 1.9a,b

  1. Mean ± SD from 13–19 rats/group.
  2. AdC adenocarcinoma, In Situ C in situ carcinoma, SCC squamous cell carcinoma, SCC squamous cell carcinoma.
  3. ap ≤ 0.001 comparing air control versus 5AZA aqueous or dry powder.
  4. bp ≤ 0.003 comparing 5AZA aqueous versus dry powder.
Back to article page